Cocrystal Pharma (NASDAQ:COCP) Trading Down 2.1% – Should You Sell?

Cocrystal Pharma, Inc. (NASDAQ:COCP)’s share price traded down 2.1% during trading on Monday . The stock traded as low as $0.93 and last traded at $0.93. 16,486 shares traded hands during trading, a decline of 63% from the average session volume of 44,991 shares. The stock had previously closed at $0.95.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Cocrystal Pharma Stock Down 2.1%

The company’s fifty day moving average price is $1.05 and its two-hundred day moving average price is $1.11. The firm has a market cap of $12.82 million, a PE ratio of -1.27 and a beta of 1.41.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The company had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.23 million. As a group, analysts predict that Cocrystal Pharma, Inc. will post -0.69 earnings per share for the current year.

Hedge Funds Weigh In On Cocrystal Pharma

An institutional investor recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC purchased a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma at the end of the most recent reporting period. 6.72% of the stock is currently owned by institutional investors.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.